Transitioning Multiple Myeloma Care from Academic to Community Settings

In this episode, experts discuss the importance of effectively transitioning patients receiving bispecific antibodies from academic centers to community practices. Panelists emphasize that access and equity remain central challenges, particularly for patients who live far from major cancer centers. They note that although initiation of therapy and management of early toxicities such as cytokine release syndrome and neurotoxicity often require experienced academic teams, risk decreases significantly after the step-up phase, making community-based care both feasible and beneficial. Experts stress the need for clear communication and structured handoff processes to prevent fragmentation of care, especially regarding infection prevention, monitoring, and supportive measures like IVIG. They highlight that empowering community clinicians through education and partnerships can reduce travel burdens and improve continuity for patients. The conversation underscores that thoughtful coordination between academic and community settings is essential as bispecific therapies expand across treatment lines.